Ibrutinib (Imbruvica) with rituximab for Waldenström's macroglobulinaemia – untreated or previously treated patients
NIHR HSRIC
Record ID 32016001028
English
Authors' recommendations:
Ibrutinib is a new drug to treat Waldenström's macroglobulinaemia, which is a rare type of slow growing cancer called non-Hodgkin lymphoma. It develops when a type of white blood cells, called plasma cells, become abnormal and grow out of control. Ibrutinib is taken as a tablet in combination with a chemotherapy drug called rituximab. Some studies have suggested this combination may offer a useful additional treatment option for patients with Waldenström's macroglobulinaemia.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/ibrutinib-imbruvica-with-rituximab-for-waldenstroems-macroglobulinaemia-untreated-or-previously-treated-patients/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Tyrosine Kinase Inhibitors
- Rituximab
- Waldenstrom Macroglobulinemia
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.